Antibody-Drug Conjugates 2011 - A Technology, Stakeholder and R&D Pipeline Analysis

This report "Antibody-Drug Conjugates 2011 - real breakthrough still to come: A Technology, Stakeholder and R&D Pipeline Analysis" published in September 2011 provides the most complete compilation of information about antibody-drug conjugate (ADC) companies, technologies and products in R&D. A comprehensive analysis of the state of the art and key trends guides the reader through this complex subject. Stakeholders in the field of antibody-drug conjugates are analysed and their contribution to the growth ADC technology and products is assessed. A critical appraisal of the clinical results of active and discontinued ADC projects and products is provided. ADC technologies and products are challenged for their commercial value and growth potential.

Scope of the report
Drugs and Linkers Used in Antibody-Drug Conjugates
Antibodies Used in Antibody-Drug Conjugates
Analysis of Stakeholders in Antibody-Drug Conjugates
Clinical Value of Antibody-Drug Conjugates
R&D Pipeline Analysis of Antibody-Drug Conjugates
Commercial Values of Antibody-Drug Conjugates
Company Profiles
Executive ADC Profiles

The recent approval of Seattle Genetics' antibody-drug conjugate Adcetris has raised great enthusiasm among stakeholders in this field. Accelerated approval was based on stunning tumor response rates in relapsed Hodgkin's lymphoma and anaplastic large cell lymphoma. Analysts expect strong sales of the expensive therapy. However, the FDA request post-approval studies showing that the high response rates translate into improved survival and that the clinical benefit seen in a small study population of 160 patients can be confirmed in a larger population. Although these data do not have to delivered before 2018, Genentech will be the next company after Wyeth (now Pfizer) to come up with survival data of its solid tumor ADC trastuzumab emtansine expected for 2012-2014. So far, only two controlled studies with ADC compounds have been published: one with Mylotarg failed to show a survival benefit, but t-DM1 pleased with an improved safety profile versus the combination of naked antibody with systemic chemotherapy

Results of early stage clinical trials of a number of ADC projects promise anti-tumor activity in hematologic malignancies as well as in solid tumors, but also dose-limiting toxicities which still narrow the therapeutic window for the currently used drugs and linkers. Nevertheless, about half of the currently clinical stage ADC projects entered clinical development within the last year indicating a high interest in the industry which also is reflected by the numerous licensing deals of the technology providers with pharmaceutical and biotech companies. The attrition rate of ADC development projects so far is well within the rate in oncology, or even better. However, ADC technologies still can be improved and candidates are emerging but need more time for validation and maturation.

Features and Benefits
Understand available drug-linker technologies
Identify key trends of novel ADC concepts and drug-linker technologies
Understand the complexity of the chemistry, manufacturing and control of ADC products and which approaches can taken to reduce it
Perceive a realistic target profile of current ADC compounds and how it can be improved;
Understand which tumor antigens are targeted by ADCs and their role
See which companies can provide solutions
Understand the commercial value of ADC technologies and ADC products

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/79167/antibody-drug-conjugates-2011-real-breakthrough-still-to-come-a-technology-stakeholder-and-rd-pipeline-analysis.html